MedTrace Logo

Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis

NCT01241214 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 579

Last updated 2019-05-15

No results posted yet for this study

Summary

This study will assess the efficacy and safety of different doses of ACT-129968 in adult patients with seasonal allergic rhinitis, due to mountain cedar pollen.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

ACT-129968

ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily

DRUG

ACT-129968

ACT-129968 (Dose 4) \& matching placebo administered orally once daily

DRUG

Cetirizine

Ceterizine administered once daily

DRUG

Placebo

Matching placebo administered twice daily.

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Sara Mangialaio, MD · Actelion

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01241214 on ClinicalTrials.gov